0001127602-24-007634.txt : 20240229 0001127602-24-007634.hdr.sgml : 20240229 20240229163700 ACCESSION NUMBER: 0001127602-24-007634 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240227 FILED AS OF DATE: 20240229 DATE AS OF CHANGE: 20240229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Klinger Shannon Thyme CENTRAL INDEX KEY: 0001866132 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 24704453 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE STREET 2: SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-02-27 0001682852 Moderna, Inc. MRNA 0001866132 Klinger Shannon Thyme 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139 1 Chief Legal Officer 0 Common Stock 7912 D Stock Option (Right to Buy) 96.20 2024-02-27 4 A 0 23635 0 A 2025-02-27 2034-02-27 Common Stock 23635 23635 D Restricted Stock Units 0 2024-02-27 4 A 0 12377 0 A Common Stock 12377 12377 D Stock Option (Right to Buy) 96.20 2024-02-27 4 A 0 60216 0 A 2025-02-27 2034-02-27 Common Stock 60216 60216 D Restricted Stock Units 0 2024-02-27 4 A 0 10609 0 A Common Stock 10609 10609 D 25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. 50% of this option will vest and become exercisable on February 27, 2026 and the remaining 50% will vest and become exercisable on February 27, 2027, subject to the recipient's continued service. 25% of the shares subject to this restricted stock unit award will vest on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. /s/ Brian Sandstrom, as Attorney-in-Fact 2024-02-29